Pardon, we have upgraded and moved this topic here
What follows has not been updated and will not be updates, but could still be useful
First Primary Therapy for Previously Untreated Lymphomas
Search First line Therapies for Lymphoma
What's New
|
R-CHOP + Azacytidine
See for Azacytidine
Condition: Previously untreated Diffuse Large B-cell Lymphoma
|
Untreated Diffuse Large B-Cell Lymphoma /
aggressive b-cell lymphoma
Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.
|
R-CHOP + Azacytidine
See for Azacytidine
Condition: Previously untreated Diffuse Large B-cell Lymphoma
|
|
R-CHOP Versus. Dose-Adjusted EPOCH-R With Molecular Profiling
Condition: Previously untreated Diffuse Large B-cell Lymphoma
|
|
Lenalidomide (Revlimid), plus CHOP-R
See for Lenalidomide
Condition: Previously untreated Diffuse Large B-cell Lymphoma
|
|
Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy
Condition: Previously untreated Diffuse Large B-cell Lymphoma
|
|
Rituxan + CHOP versus Dose-Adjusted EPOCH-Rituxan with molecular Profiling
Condition: Previously untreated Diffuse Large B-cell Lymphoma
|
|
Bexxar with CHOP-Rituxan (SWOG-0433)
Condition: Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL
|
|
Vorinostat (Zolinza* ), Rituxan, and Combination Chemotherapy
See for Zolinza
Condition: Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
|
|
RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
See for Everolimus (RAD001)
Condition: high risk Diffuse Large B-Cell Lymphoma in complete response
|
CNS Lymphoma
|
Temozolomide-based Clinical trials: http://bit.ly/cTcM0O
Report http://bit.ly/biziKd
|
Untreated Follicular Lymphoma or Low Grade Lymphoma
Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.
Search: first line for indolent lymphomas
Early stage:
|
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma
|
New combinations:
|
Combination Veltuzumab (Anti-CD20) AND
Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy
Condition: Patients With Follicular Lymphoma
|
|
Rituxan, Cyclophosphamide, Velcade, and Prednisone
Condition: Previously untreated stage III or IV follicular and Marginal Zone lymphomas
|
|
Bendamustine, Mitoxantrone, and Rituximab (BMR)
Condition: Previously untreated high risk follicular lymphoma
(as defined by a FLIPI score >/= 3.)
|
|
Lenalidomide (Revlimid), Rituxan, and Combination Chemotherapy
Condition: Previously untreated follicular lymphoma, stage II-IV
|
Radioimmunotherapy-based:
|
Low-Dose MTX and Bexar for Untreated Follicular Lymphoma
"In addition to evaluating the occurrence of HAMA, this research study will also look at the short and long-term effectiveness of this combination in the treatment of lymphoma, as well as its safety."
|
|
Dose-Response in Radioimmunotherapy of Lymphoma
Condition: Eligible, by standard of care criteria, for Bexxar or Zevalin treatment
|
|
Bexxar or Zevalin as First Therapy of Lymphoma
Condition: Previously untreated b-cell lymphoma
|
|
Bexxar, Rituxan, and Combination Chemotherapy
Condition: Previously untreated stage III or IV follicular lymphoma
|
|
Zevalin Following R-CVP versus Observation
Condition: Previously untreated high risk follicular lymphoma as defined by a follicular lymphoma international prognostic index (FLIPI) of 3, 4, or 5 assessed within 3 months prior to randomization."
|
Untreated Mantle Cell lymphoma
Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.
|
Bexxar followed by six cycles of CHOP Condition: Previously untreated Mantle Cell Lymphoma
|
|
Vaccine with Interleukin-2 After Combination Chemotherapy Condition: Previously treated, or untreated, Mantle Cell Lymphoma
|
Untreated T-cell lymphoma (under construction)
Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.
|
Brentuximab Vedotin Given Sequentially and Combined With CHOP http://1.usa.gov/fgBeT3
Condition: Anaplastic Large Cell Lymphoma
"Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody linked to a potent, synthetic drug payload, monomethyl auristatin E (MMAE)"
Clinical report: http://www.ncbi.nlm.nih.gov/pubmed/21047225
|
|
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Conditions: Peripheral T Cell Lymphoma, Unspecified; Angioimmunoblastic Lymphadenopathy; AIL Type Lymphoma; Anaplastic Large Cell Lymphoma, ALK Negative; Extranodal NK/T-Cell Lymphoma
|
|
Alemtuzumab and CHOP in T-cell Lymphoma
Conditions: Lymphoma, T-Cell, Peripheral
|
|
CHOP and ONTAK
Conditions: Treatment naïve, except for prior radiation or a single cycle of CHOP
T-Cell lymphoma, REAL classification
|
Untreated Hodgkins lymphoma (under construction)
Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.
|
KGEL Vaccine After Initial Chemotherapy
Condition: Previously untreated Hodgkin's Disease
|
Untreated CLL/SLL (under construction)
Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.
|
Lenalidomide as Initial Treatment, Age 65 and Older
|
|
Fludarabine and Rituxan Followed by Bexxar Conditions: Previously untreated: Chronic Lymphocytic Leukemia (CLL) ;
Small Lymphocytic Lymphoma (SLL)
|
|